Neuromuscular Disorders


click here to return to the Clinical Trials page


Ongoing Clinical Trials


A Double-Blind, Randomized, Multicenter, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  • The study is designed to evaluate the efficacy and safety of fingolimod in the treatment of CIDP compared with placebo.
  • Eligibility:
    1. Diagnosis of typical CIDP
    2. Disability defined by an INCAT Disability Scale score of 1-9
    3. Receiving IVIg treatment (minimal dose equivalent to 0.4 g/kg every 4 weeks for a minimum of 12 weeks)
    4. Male or female, aged 18 years or older
  • Exclusion Criteria:
    1. Patients should not have diabetes
    2. Patients with multifocal motor neuropathy or IgM paraproteinemia cannot be included 
  • Sponsor: Novartis
  • Principal Investigator: Kourosh Rezania MD
  • Study Coordinator: Elizabeth Londo